We have previously detected an increased frequency of loss of heterozygosity (LOH) on chromosome 18q during progression of colorectal carcinomas. To clarify the target of 18qLOH, mutation of Smad4 and Smad2 genes was analysed in 176 colorectal tumors with dierent stages, including liver metastasis, from 111 sporadic, 52 familial adenomatous polyposis (FAP) and nine hereditary nonpolyposis colorectal cancer (HNPCC) patients. Mutation of other Smad gene families in the TGF-b signaling pathway was also examined. Twenty-one Smad4 mutations and one Smad2 mutation were detected, whereas mutation of Smad3, 6 and 7 genes was not detected. Smad4 mutations included seven frameshift, one inframe deletion, four nonsense and nine missense mutations, 95% of which resulted in alteration of Smad4 protein regions included in homo-oligomer and hetero-oligomer formation. Frequencies of tumors with Smad4 mutation were 0/40 (0%) in adenoma, 4/39 (10%) in intramucosal carcinoma, 3/44 (7%) in primary invasive carcinoma without distant metastasis, 6/17 (35%) in primary invasive carcinoma with distant metastasis, and 11/36 (31%) in distant metastasis (metastatic/non-metastatic: P=0.006 *0.01). Loss of the other allele was observed in 19 of 20 (95%) invasive and metastasized carcinomas with Smad4 mutations. In four cases both primary and metastasized carcinomas in the same patients showed the same mutations. The present results suggest that Smad4 gene is one of true targets of 18qLOH, and that its inactivation is involved in advanced stages, such as distant metastasis, in human colorectal carcinogenesis.
Introduction
Colorectal carcinogenesis, in the majority of cases, develops through multistages, such as by the adenomacarcinoma sequence (Vogelstein et al., 1988; Miyaki et al., 1990 Miyaki et al., , 1995 .
During these sequences, contribution of inactivation of tumor suppressor genes: APC and p53, has been widely recognized. Several other tumor suppressor genes have been suggested to exist on chromosomes 1p, 8p, 18q, and 22q, and inactivation of these genes may be involved in the later stages of colorectal carcinogenesis, since loss of heterozygosity (LOH) at these regions has been detected in carcinomas at advanced stages (Vogelstein et al., 1988; Miyaki et al., 1990 Miyaki et al., , 1995 . With respect to 18q, DCC gene has been isolated as a candidate target tumor suppressor gene , and loss of expression of DCC gene has frequently been observed in advanced carcinomas Kikuchi-Yanoshita et al., 1992a) . However, there have been several cases in which loss of expression did not correlate with LOH (Kikuchi-Yanoshita et al., 1992a) , and mutation in the coding region of DCC gene has seldom been detected . Two other candidate genes: Smad4 (DPC4) and Smad2 (MADR2) have recently been identi®ed at the same 18q region Eppert et al., 1996; Riggins et al., 1996) , and a high frequency of Smad4 gene mutation has been detected in pancreatic carcinomas , suggesting that Smad4 gene is the target tumor suppressor gene for 18qLOH.
Mutations of Smad4 and Smad2 genes have been detected in some colorectal carcinomas (Eppert et al., 1996; Thiagalingam et al., 1996; Takagi et al., 1996; MacGrogan et al., 1997) ; however, the frequencies of these mutations have been found to be low, and the role of these genes in colorectal carcinogenesis is still unclear. To clarify the contribution in colorectal carcinogenesis, we analysed mutation of Smad4 and Smad2 genes in dierent stages of tumor. These genes are involved in signal transduction of TGF-b, which is a growth inhibitory regulator of epithelial cells, and there are other genes known to function in the same signal pathway (Massague, 1996) . To study the contribution of these other genes in colorectal carcinogenesis, we also analysed mutation of Smad3 (Zang et al., 1996 ), 6 (Riggins et al., 1996 and 7 (Nakao et al., 1997) genes.
Results
One hundred and seventy-six colorectal tumors were obtained from 111 sporadic, 52 familial adenomatous polyposis (FAP), and nine hereditary nonpolyposis colorectal cancer (HNPCC) patients; the tumors were classi®ed into adenoma, intramucosal carcinoma, primary invasive carcinoma without distant metastasis, primary invasive carcinoma with distant metastasis and carcinoma metastasized to liver and other distant tissues. DNA from these tumors was analysed for Smad4 mutation using PCR ± SSCP and direct sequencing methods. In 44 cases among these tumors from which poly(A)RNA was obtained, mutation of Smad2, 3, 6 and 7 was analysed by means of the RT ± PCR ± SSCP method.
Characteristics of Smad4 and Smad2 gene mutations
As shown in Figure 1 and Table 1 , we detected 21 somatic mutations of Smad4 gene in 20 colorectal carcinomas from 13 sporadic, six FAP, and 1 HNPCC patients. Seven mutations (33%) were 1 ± 28-bp deletions, one mutation (5%) was 1-bp insertion, and 13 mutations (62%) were single-base-pair substitutions. Single-base-pair substitutions included four nonsense and nine missense mutations and 54% (7/13) of them were CG to TA transitions. Deletion, insertion, and nonsense mutations resulted in truncation of predicted Smad4 protein without all or part of the MH2 (mad homology 2) region, which is necessary for homotrimer formation of Smad4 protein and heterooligomer formation between Smad4 and Smad2 or 3 proteins (Shi et al., 1997) . The majority of missense mutations clustered in the regions that participate homo-and hetero-oligomer formation, except for one mutation in the MH1 region, and a hot spot of missense mutation (Arg to His) was observed at codon 361 ( Figure 2) .
Loss of the normal allele was detected in 19 out of 20 (95%) invasive and metastatic (primary and metastasized) carcinomas from sporadic and FAP cases with Smad4 gene mutations, whereas two of four (50%) intramucosal carcinomas with Smad4 mutations showed loss of the other allele. One FAP intramucosal carcinoma (PLK63T2) showing two alleles had two missense mutations, and an HNPCC Cases in which both primary and metastasized carcinomas had the same mutations Smad4 mutation in metastatic colorectal cancer M Miyaki et al carcinoma (HNP10Ca2), which retained two alleles, had a GA deletion at GAGAGA dinucleotide repeats.
Frequency of Smad4 gene mutation and tumor stage
The frequency of Smad4 mutation increased as the stage of colorectal tumors advanced ( Table 2 ). The frequencies were 0% (0/40) in adenomas, 10% (4/39) in intramucosal carcinomas, 7% (3/44) in invasive carcinomas without distant metastasis, 35% (6/17) in primary invasive carcinomas with distant metastasis, and 31% (11/36) in carcinomas metastasized to the liver and distant lymph nodes, and disseminated. Mutation frequency was analysed, by Fisher's exact probability test, for primary invasive carcinoma without distant metastasis versus both primary invasive carcinoma with distant metastasis and carcinoma metastasized to distant tissue, and the P-values were 0.01 and 0.006, respectively. In four cases, in which primary and metastasized carcinomas could be analysed in the same patients, both carcinomas showed SSCP patterns corresponding to the same mutation, although metastasized carcinoma showed more obvious mutant band and loss of normal allele (Figure 3 ).
In the case of intramucosal carcinomas, all four cases showing Smad4 mutation were from FAP patients, and that had developed to large sizes, such as 30 mm. No Smad4 mutation was detected in the sporadic intramucosal carcinomas analysed. Mean sizes of FAP and sporadic intramucosal carcinomas without Smad4 mutation were 15 mm, respectively.
Mutation in Smad3, Smad6 and Smad7 genes
Of 44 colorectal tumors, one invasive carcinoma from an FAP patient showed somatic mutation of Smad2 gene without loss of normal allele, which was the missesense mutation that occurred in the MH2 region (Table 1) . There were no mutation of Smad3, Smad6 and Smad7 genes in the 44 tumors.
Discussion
A high frequency of LOH on chromosome 18q has been recognized in the progression of carcinomas of the colon (Vogelstein et al., 1988; Miyaki et al., 1990) and other tissues, including the pancreas (Hahn et al., 1995) . This suggested the presence of tumor suppressor gene(s) at this region. But mutation of DCC gene isolated from this region has Included 29 liver metastases, two distant lymph node metastases, one brain metastasis, one skin metastasis and two disseminations from sporadic cases, and one liver metastasis from a FAP; d In four cases, both primary and metastasized carcinomas from the same patients were analysed. In all four of these cases both primary and metastasized carcinomas had the same mutations. P-value of mutation frequency for primary invasive carcinoma without distant metastasis versus primary invasive carcinoma with distant metastasis was 0.01 and that for primary invasive carcinoma without distant metastasis versus metastasized carcinoma was 0.006
Figure 3 PCR ± SSCP patterns of Smad4 gene in primary and metastasized carcinomas from the same patients. In cases of PLK112 and PLK229, both primary carcinoma and liver metastasis showed the same abnormal bands corresponding to the same mutation Cho et al., 1996) . Since the Smad4 gene was isolated from the same region as a tumor suppressor gene for pancreatic cancer , mutation analyses of this gene have been carried out on cancers in various other organs. A rather low frequency of mutation (510%) has been found (Schutte et al., 1996) , compared to the high frequency of alteration of this gene in pancreatic carcinomas (mutation in 20% and homozygous deletion in 30% of tumors). In the case of colorectal cancer, about ten mutations of Smad4 gene have been detected Takagi et al., 1996; MacGrogan et al., 1997) , the frequency being nearly 20%, which was low compared to 60% or more of 18qLOH. It has therefore been concluded that the extent of contribution of Smad4 mutation to colorectal carcinogenesis may be insignificant. However, there has been no classi®cation of tumor stages in regard to mutational frequency of Smad4 gene. To clarify the correlation of this mutation with the progressive stages of colorectal tumors, mutation was analysed in the present study in ®ve categories, including distant metastasis. We detected 21 Smad4 gene mutations, and found an increase in mutation frequency with the progression of stages, especially with distant metastasis. Metastatic carcinoma including carcinomas metastasized to the liver and other distant tissues, showed an obviously higher frequency (31 ± 35%) than invasive carcinoma without distant metastasis (7%), intramucosal carcinoma (10%) and adenoma (0%). The presence of the same Smad4 mutations in both primary carcinomas and distant metastases observed in the same patients suggested that Smad4 mutation had occurred in the primary carcinomas, and some of the cell population having Smad4 mutation then metastasized to distant tissues. Therefore, presence of Smad4 mutation in primary carcinoma may be a prognostic marker.
Although there were no Smad4 mutations in sporadic intramucosal carcinomas, some large samples of intramucosal carcinoma from FAP patients showed the Smad4 mutation. This may suggest that progression of colorectal tumors is more rapid in FAP than in sporadic patients. Smad4 mutation occurring in a large advanced HNPCC carcinoma was a GA deletion at GAGAGA repeated sequence, and it was assumed to be caused by the lack of mismatch repair function, similar to the A deletion at (A) 10 region of TGFbRII gene and at (G) 8 region of BAX gene caused in this carcinoma.
Smad4 mutations detected in the present analysis included frameshift, nonsense, and missense mutations. More than 95% of these mutations resulted in alteration of Smad4 protein regions involved in homo-oligomer and hetero-oligomer formation with Smad2 protein (Shi et al., 1997) , and there was a hot spot of missense mutation at codon 361, which disrupts both homo-and hetero-oligomerization. With respect to directions of Smad4 mutation, 33% were deletions, 5% were insertions, and 62% were single-base-pair substitutions. Of these single-base-pair substitutions, 54% were transition from CG to TA, and this frequency was lower than that of APC (65%) (Miyaki et al., 1994) and p53 mutations (73%) (Kikuchi-Yanoshita et al., 1992b) previously observed in colorectal tumors. This suggests that the mechanism or factors causing Smad4 mutation at more advanced stages are somewhat dierent from those causing APC and/or p53 mutation at adenoma formation and/or conversion of adenoma into early carcinoma.
In addition to mutation, 19 of 20 (95%) invasive and metastastic carcinomas with Smad4 mutation showed loss of the other allele, suggesting that biallelic alteration results in the inactivation of Smad4 protein, which is one important mediator in the TGF-b signaling pathway in the regulation of epithelial cell growth. Regarding the correlation of Smad4 gene mutation with 18qLOH, the absence of Smad4 mutation in adenoma and a low mutation frequency in intramucosal carcinoma are consistent with low frequencies of 18qLOH in these tumors. However, mutation frequency in invasive carcinomas, including metastasis (31 ± 35%), seems to be lower compared to 18qLOH previously detected in the advanced carcinomas (50 ± 80%) (Miyaki et al., 1990 (Miyaki et al., , 1995 , and that detected in the present study (Table  2) . Such a frequency dierence may also exist in the case of pancreatic cancer, in which frequency of Smad4 gene alteration (50%: mutation in 20% of tumors, and homozygous deletion in another 30% of tumors) appears to be lower than 18qLOH (about 90%) (Hahn et al., 1995; Schutte et al., 1996) . Homozygous deletion of 18qLOH has also been reported in 2/18 and 2/9 colorectal carcinomas MacGrogan et al., 1997) ; therefore, if homozygous deletion was analysed in our sample and found to occur in a similar frequency, Smad4 gene alteration might correspond to around half of 18qLOH in advanced colorectal carcinoma, which may be higher than the previously estimated incidence.
A ®nding on intestinal tumorigenesis in the compound mutant mice of both Smad4 and APC genes has indicated the signi®cant contribution of Smad4 mutation to progression of colorectal tumors (Takaku et al., 1998) . Germline mutation of Smad4 gene have been identi®ed in juvenile polyposis, which is an autosomal dominant disease with predisposition to polyps and gastrointestinal cancer (Howe et al., 1998) . These two recent ®ndings also support the signi®cant involvement of Smad4 mutation in colorectal carcinogenesis.
Although possible existence of additional unknown target tumor suppressor gene(s) in the region of 18qLOH cannot be completely ruled out, our present results strongly suggest a signi®cant contribution of Smad4 gene inactivation in advanced stages, such as distant metastasis, of human colorectal carcinogenesis. Contribution of Smad2 gene mutation is rather small, and loss of expression of DCC gene may not be the cause but a consequence of carcinogenesis. The contribution of alterations in Smad3, 6, and 7 genes at chromosomes other than 18 is quite low. From the present and previous (Konishi et al., 1996) results, it may be concluded that alteration of TGF-b signaling pathway is involved in human colorectal carcinogenesis mainly through two dierent events: one through inactivation of TGFbRII gene at an early stage of carcinogenesis in HNPCC cases, and another through inactivation of Smad4 gene at later stages in sporadic and FAP cases. 
Materials and methods

Tumor samples
One hundred and seventy-six colorectal tumors analysed for mutation of Smad4 gene were classi®ed into ®ve categories; adenoma, intramucosal carcinoma, primary invasive carcinoma without distant metastasis, primary invasive carcinoma with distant metastasis, and carcinoma metastasized to distant tissue. Adenomas included 20 from sporadic cases and 20 from FAP patients. Intramucosal carcinomas included 18 from sporadic cases, 21 from FAP. Invasive carcinomas without distant metastasis included 26 from sporadic cases, nine from FAP, and nine from HNPCC. Primary invasive carcinomas with distant metastasis included 15 with liver metastasis and one with distant lymph node metastasis from sporadic cases, and one with ovary metastasis from an FAP. Carcinomas metastasized to distant tissues included 29 liver metastases, two distant lymph node metastases, one brain metastasis, one skin metastasis and two disseminations from sporadic cases, and one liver metastasis from an FAP. In four sporadic cases, both primary and metastasized carcinomas were obtained. Invasive carcinomas with nearby micro lymph node metastases were not included in metastatic carcinomas. Tumors analysed for mutation of Smad2, 3, 6, and 7 genes included one adenoma, four intramucosal carcinomas, 20 invasive carcinomas without metastasis and 19 metastatic carcinomas. All specimens were obtained after surgical removal of the tumors and frozen at 7708C until analysis. Analysis of these samples was approved by the Komagome Hospital Review Committee.
DNA and RNA extraction
DNA was extracted from each tumor and the corresponding normal tissue using Pronase K, sodiumdodecyl sulfate, and phenol-chloroform. Total RNA was extracted from tumor tissue using homogenization with guanidinium thiocyanatesodium dodecyl sarcosinate followed by centrifugation on a cushion of CsCl solution. Poly(A)RNA was prepared from total RNA by chromatography on oligo(dT)-cellulose.
Mutation analysis of Smad genes
DNA samples were ampli®ed for SSCP analysis (Orita et al., 1989) of the Smad4 gene using PCR (5 min at 978C, once; 1 min at 958C, 1 min at 588C, and 1 min at 728C, for 35 cycles; and 10 min at 728C, once). The reaction mixture (6 ml) contained 200 ng of genomic DNA, the proper pair of each 0.2 mM primer, 25 mM of each four dideoxynucleotide triphosphate, 16PCR buer, Taq polymerase and [a-32 P]dCTP. Sequences of primers used for ampli®cation of each exon were the same as those described (Schutte et al., 1996) , shown in their internet address. PCR products were diluted ®vefold with formamide dye solution, and a 2 ml sample of the diluted reaction mixture was heated for 5 min at 808C, followed by SSCP analysis in 5% polyacrylamide gel containing 5% glycerol. After electrophoresis at 20 ± 258C, the gel was exposed to X-ray ®lm at 7708C. Aberrant singlestranded DNA fragments, which were present in DNAs from tumors but were absent in DNAs from the corresponding normal tissues, were extracted with distilled water from the PCR ± SSCP gels. The DNA fragments were ampli®ed through asymmetrical PCR in a 100-ml mixture under the same conditions as those for PCR ± SSCP analysis, with the exception that the ratio of primers was 100/1 or 1/100 for sense and antisense primers, respectively. The ampli®ed DNA samples were puri®ed using the QIAquick PCR puri®cation kit (QIAGEN Inc., Germany) and sequenced with the dideoxy chaintermination reaction using Sequenase Version 2.0 (Amarsham Life Science Inc., USA) as previously described (Miyaki et al., 1994) .
Poly(A)RNA samples (1 mg each) were reverse transcribed in 15 ml reaction mixture using the First-strand cDNA synthesis kit (Pharmacia Biotech Inc. Sweden) containing random hexadeoxynucleotides, and aliquots (0.3 ml each) of the cDNA products were analysed for mutation of Smad2, 3, 6 and 7 genes by PCR ± SSCP method under the same conditions as those used for Smad4 mutation analysis in DNA samples. Sequences of primers used for ampli®cation of Smad2, 3, 6 and 7 cDNAs were determined based on the previous reports (Eppert et al., 1996; Riggins et al., 1996; Zang et al., 1996; Nakao et al., 1997) . These primers were designed to amplify each cDNA within 3 ± 6 overlapping regions.
Analysis of 18qLOH
DNAs from tumors and the corresponding normal tissues were digested with appropriate restriction endonuclease, and subjected to the Southern blot hybridization with the probe, p15-65, D18S5 or PALB, as previously described (Miyaki, et al., 1990) . Some tumors were analysed for 18qLOH after ampli®cation of DNA by PCR using microsatellite primers, D18S46 and D18S858, under the same conditions as reported previously (Konishi et al., 1996) .
Statistical method
Frequency of Smad4 gene mutation was compared between invasive carcinomas without distant metastasis and primary invasive carcinomas with distant metastasis, and between invasive carcinomas without distant metastasis and carcinomas metastasized to distant tissues, using Fisher's exact probability test.
